-
1
-
-
79952821291
-
Summary of Product Characteristics (SPC) Azarga®
-
Summary of Product Characteristics (SPC) Azarga®. Alcon Pharma, 2008.
-
(2008)
Alcon Pharma
-
-
-
2
-
-
0345337696
-
-
Bundesinstitut fur Arzneimittel und Medizinprodukte website, Accessed September 24, 2010
-
Bundesinstitut fur Arzneimittel und Medizinprodukte website. Arzneimittelgesetz (AMG). http://www.bfarm.de/EN/BfArM/BfArMService/AMG_en/amg-node-en.html. Accessed September 24, 2010.
-
Arzneimittelgesetz (AMG)
-
-
-
3
-
-
74549215576
-
Repeatability and reproducibility for intraocular pressure measurement by dynamic contour, ocular response analyzer, and goldmann applanation tonometry
-
Sullivan-Mee M, Gerhardt G, Halverson KD, Qualls C. Repeatability and reproducibility for intraocular pressure measurement by dynamic contour, ocular response analyzer, and goldmann applanation tonometry. J Glaucoma. 2009;18(9):666-673.
-
(2009)
J Glaucoma
, vol.18
, Issue.9
, pp. 666-673
-
-
Sullivan-Mee, M.1
Gerhardt, G.2
Halverson, K.D.3
Qualls, C.4
-
5
-
-
79952826677
-
-
Whitehouse Station, NJ: Merck & Co., Inc
-
COSOPT [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2006.
-
(2006)
COSOPT [package Insert]
-
-
-
6
-
-
57349119300
-
A one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared to BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular hypertension
-
for the Brinzolamide/Timolol Comfort Study Group
-
Vold SD, Evans RM, Stewart RH, et al; for the Brinzolamide/Timolol Comfort Study Group. A one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared to BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharm Ther. 2008;24(6):601-605.
-
(2008)
J Ocul Pharm Ther
, vol.24
, Issue.6
, pp. 601-605
-
-
Vold, S.D.1
Evans, R.M.2
Stewart, R.H.3
-
7
-
-
67651183720
-
The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension
-
Manni G, Denis P, Chew P, et al. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2009;18(4):293-300.
-
(2009)
J Glaucoma
, vol.18
, Issue.4
, pp. 293-300
-
-
Manni, G.1
Denis, P.2
Chew, P.3
-
8
-
-
77955380703
-
Factors related to glaucoma treatment compliance: Patients' opinions from a university hospital
-
Silva LR, de Paula JS, Rocha EM, Rodrigues Mde L. Factors related to glaucoma treatment compliance: patients' opinions from a university hospital. Arq Bras Oftalmol. 2010;73(2):116-119.
-
(2010)
Arq Bras Oftalmol
, vol.73
, Issue.2
, pp. 116-119
-
-
Silva, L.R.1
de Paula, J.S.2
Rocha, E.M.3
Rodrigues, M.L.4
-
9
-
-
35848945084
-
Ocular comfort of combination glaucoma therapies: Brimonidine 0.2%/timolol 0.5% compared with dorzolamide 2%/timolol 0.5%
-
Chan K, Testa M, McCluskey P. Ocular comfort of combination glaucoma therapies: brimonidine 0.2%/timolol 0.5% compared with dorzolamide 2%/timolol 0.5%. J Ocul Pharmacol Ther. 2007;23(4): 372-376.
-
(2007)
J Ocul Pharmacol Ther
, vol.23
, Issue.4
, pp. 372-376
-
-
Chan, K.1
Testa, M.2
McCluskey, P.3
-
10
-
-
0141928070
-
Compliance barriers in glaucoma: A systematic classification
-
Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003;12(5):393-398.
-
(2003)
J Glaucoma
, vol.12
, Issue.5
, pp. 393-398
-
-
Tsai, J.C.1
McClure, C.A.2
Ramos, S.E.3
-
11
-
-
0033736217
-
Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting
-
Barnebey H, Kwok SY. Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting. Clin Ther. 2000;22(10):1204-1212.
-
(2000)
Clin Ther
, vol.22
, Issue.10
, pp. 1204-1212
-
-
Barnebey, H.1
Kwok, S.Y.2
|